Hexter Joshua 4

What Happened

• Joshua Hexter, Chief Operating Officer and Chief Business Officer of Oramed Pharmaceuticals, was granted 95,889 restricted stock units (RSUs) on 2026-03-17. The reported acquisition price is $0.00 (an equity award, not a cash purchase). Each RSU represents the right to receive one share of Oramed common stock as the units vest.

Key Details

• Transaction date: 2026-03-17 (reported on Form 4 filed 2026-03-18).
• Transaction type/code: Award/Grant (A).
• Units granted: 95,889 RSUs; reported acquisition price $0.00 (award).
• Vesting: RSUs vest ratably in 8 quarterly installments beginning April 1, 2026 (i.e., over ~2 years).
• Each RSU converts to one share upon vesting (par value $0.012 per share).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Filing appears timely (reported the next day); no late-report indication in this record.

Context

• RSUs are compensation awards that convert to shares as they vest; they are not an open-market purchase or sale. Because vesting is spread over eight quarters, the award is a retention/compensation incentive rather than an immediate change in share ownership.
• This filing does not indicate any sale, exercise, or tax-withholding details. No inference about Hexter’s personal trading intent should be drawn from the award alone.